Seminars in Hematology
Volume 37, Issue 1 , Pages 81-90 , January 2000

Hematopoietic growth factors in the pathogenesis and for the treatment of aplastic anemia

  • Judith C.W Marsh

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Judith C.W. Marsh, MD, FRCP, FRCPath, Department of Haematology, St Georges Hospital Medical School Cranmer Terrace, London, SW17 ORE, UK.

References 

  1. Abkowitz JL, Hume H, Yancik SA, et al.  Stem cell factor serum levels may not be clinically relevant. Blood. 1996;87:4017–4018
  2. Antin JH, Smith BR, Holmes W, et al.  Phase I/II study of rhGM-CSF in aplastic anemia and myelodysplastic syndromes. Blood. 1988;72:705–713
  3. Atkins MB, Kappler K, Mier JW, et al.  Interleukin-6 associated anemia: Determination of the underlying mechanism. Blood. 1995;86:1288–1291
  4. Bacigalupo A, Biaggio G, Figari O, et al.  Response of CFU-GM to increasing doses of rhGM-CSF in patients with aplastic anemia. Exp Hematol. 1991;19:829–834
  5. Bacigalupo A, Broccia G, Corda G, et al.  Antilymphocyte globulin, cyclosporin and granulocyte colony stimulating factor in patients with acquired severe aplastic anaemia (SAA): A pilot study of the EBMT SAA Working Party. Blood. 1995;85:1348–1353
  6. Bacigalupo A, Piaggio G, Podesta M, et al.  Collection of peripheral blood haemopoietic progenitors (PBHP) from patients with severe aplastic anemia (SAA) after prolonged administration of granulocyte colony stimulating factor. Blood. 1993;82:1410–1414
  7. Bagnara GP, Strippoli P, Bonsi L. Effect of stem cell factor on colony growth from acquired and constitutional (Fanconi) aplastic anaemia. Blood. 1992;80:382–387
  8. Ball SE, Gibson FM, Rizzo S, et al.  Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582–3592
  9. Bessho M, Hirashima K, Asano S, et al.  Treatment of anaemia of aplastic anaemia patients with rh EPO in combination with G-CSF: A multicenter randomised controlled study. Eur J Haematol. 1997;58:265–272
  10. Brereton ML, Adams JA, Briggs M, et al.  The in vitro effect of pegylated recombinant human megakaryocyte growdi and development factor (PEGrHuMGDF) on megakaryopoiesis in patients widi aplastic anaemia. Br J Med. 1999;104:119–126
  11. Champlin RE, Nimer SD, Ireland P, et al.  Treatment of refractory aplastic anemia with recombinant human granulocyte-macrophage colony stimulating factor. Blood. 1989;73:694–699
  12. DePlanque M, Bacigalupo A, Wursch A, et al.  Long term follow up of severe aplastic anaemia patients treated with antithymocyte globulin. Severe Aplastic Anaemia Working Party of the European Cooperative Group for Bone Marrow Transplantation (EBMT). Br J Haematol. 1989;73:121–126
  13. Devetten MP, Young NS. Hemopoietic growth factors in the pathophysiology and treatment of aplastic anemia. In:  Ganser A,  Hoelzer D editor. Cytokines in the Treatment of Hemopoietic Failure. New York, NY: Marcel Dekker; 1999;p. 155–169
  14. Doney K, Storb R, Lilleby K, et al.  Recombinant interleukin-1 followed by immunosuppressive therapy for aplastic anemia. Am J Hematol. 1996;52:61–62
  15. Emmons RVB, Reid DM, Cohen RL, et al.  Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068–4071
  16. Engelhardt M, Ozkaynak MF, Drulinsky P, et al.  Telomere activity and telomere length in pediatric patients with malignancies undergoing chemotherapy. Leukemia. 1998;12:13–24
  17. Ganser A, Lindermann A, Seipelt G, et al.  Effect of recombinant human interleukin-3 in aplastic anemia. Blood. 1990;76:1287–1292
  18. Gascon P, Scala G. Decreased interleukin-1 production in aplastic anemia. Am J Med. 1988;85:668–674
  19. Geary CG, Marsh JCW. Is aplastic anaemia a pre-leukaemic disorder?. Br J Haematol. 1991;77:447–452
  20. Gibson FM, Gordon-Smith EC. Long term culture of aplastic anaemia bone marrow. Br J Haematol. 1990;75:421–427
  21. Gibson FM, Scopes J, Daly S, et al.  In vitro response of normal and aplastic anaemia bone marrow to mast cell growth factor and in combination with granulocyte macrophage colony stimulating factor and interleukin-3. Exp Hematol. 1994;22:302–312
  22. Gluckman E, Esperou-Bourdeau H, Boogaerts BM, et al.  Multicenter randomized study comprising cyclosporin A alone and antithymocyte globulin with prednisolone for treatment of aplastic anemia. Blood. 1992;79:2540–2546
  23. Gluckman E, Rokicka-Milewska R, Gordon-Smith EC, et al.  Results of a randomized study of glycosylated rHuG-CSF Lenograstim in severe aplastic anemia. Blood. 1998;92(suppl 1):1551; abstr
  24. Guinan EC, Sieff CA, Oette DH, et al.  A phase I/II trial of recombinant granulocyte-macrophage colony stimulating factor for children with aplastic anemia. Blood. 1990;76:1077–1082
  25. Hirayama Y, Kongo Y, Matsunaga T, et al.  Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 1993;85:676–683
  26. Hirayama Y, Sakamaki S, Matsunaga T, et al.  Concentrations of thrombopoietin in bone marrow in normal subjects, and in patients with idiopathic thrombocytopenic purpura, aplastic anemia and essential thrombocythemia correlates with its mRNA expression of bone marrow stromal cells. Blood. 1998;92:46–52
  27. Holmberg LA, Seidel K, Leisenring W, et al.  Aplastic anemia: Analysis of stromal cell function in long term marrow culture. Blood. 1994;84:3685–3690
  28. Imashuku S, Hibi S, Kataoka MY, et al.  Myelodysplasia and acute myeloid leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol. 1995;89:188–191
  29. Kaito K, Kobayashi M, Katayama T, et al.  Long term administration of G-CSF for aplastic anaemia is closely related to the early evolution of monosomy 7 MDS in adults. Br J Haematol. 1998;103:297–303
  30. Kojima S. Hemopoietic growth factors and marrow stroma in aplastic anemia. Int J Hematol. 1998;68:19–28
  31. Kojima S, Fukuda M, Miyajima Y, et al.  Treatment of aplastic anemia in children with recombinant human granulocyte-colony stimulating factor. Blood. 1991;77:937–941
  32. Kojima S, Matsuyama T. Stimulation of granulopoiesis by high-dose recombinant human granulocyte colony stimulating factor in children with aplastic anemia and very severe neutropenia. Blood. 1994;83:1474–1478
  33. Kojima S, Matsuyama T, Kodera Y. Hemopoietic growth factors released from marrow stromal cells from patients with aplastic anemia. Blood. 1992;79:2256–2261
  34. Kojima S, Matsuyama T, Kodera Y, et al.  Measurement of endogenous plasma granulocyte colony stimulating factor in patients with acquired aplastic anemia by a sensitive chemiluminescent immunoassay. Blood. 1996;87:1303–1308
  35. Kojima S, Matsuyama T, Kodera Y, et al.  Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunoabsorbent assay. Br J Haematol. 1997;97:538–543
  36. Kojima S, Matsuyama T, Kodera Y. Plasma levels and production of soluble stem cell factor by marrow stromal cells in patients with aplastic anaemia. Br J Haematol. 1997;99:440–446
  37. Kojima S, Tsuchida M, Matsuyama T. Myelodysplasia and leukemia after treatment of aplastic anemia with granulocyte colony stimulating factor. N Engl J Med. 1992;326:1294–1295
  38. Kumar M, Alter BP. Hemopoietic growth factors for the treatment of aplastic anaemia. Curr Opin Hematol. 1998;5:226–234
  39. Kurzrock R, Paquette R, Gratwohl A, et al.  Use of stem cell factor (Stemgen, SCF) and filgrastim (G-CSF) in aplastic anemia patients who have failed ATG/ALG therapy. Blood. 1997;90(suppl 1):173; abstr
  40. Kurzrock R, Talpaz M, Estrov Z, et al.  Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol. 1991;9:1241–1250
  41. Maciejewski JP, Anderson S, Katevos P, et al.  Phenotypic and functional analysis of the bone marrow progenitor cell compartment in aplastic anaemia. Br J Haematol. 1994;87:227–233
  42. Maciejewski JP, Selleri C, Sato T, et al.  A severe and consistent defect in marrow and circulating primitive hemopoietic cells (long term culture initiating cells) in acquired aplastic anemia. Blood. 1996;88:1983–1991
  43. Marsh JCW, Chang J, Testa NG, et al.  In vitro assessment of marrow ‘stem cell’ and stromal cell function in aplastic anaemia. Br J Haematol. 1991;78:258–267
  44. Marsh JCW, Chang J, Testa NG, et al.  The haemopoietic defect in aplastic anaemia assessed by long term marrow culture. Blood. 1990;76:1748–1757
  45. Marsh JCW, Gibson FM, Prue RL, et al.  Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol. 1996;95:605–610
  46. Marsh JCW, Socie G, Schrezenmeier H, et al.  Haemopoietic growth factors in aplastic anaemia: A cautionary note. Lancet. 1994;344:172–173
  47. Marsh JCW, Testa NG. Stem cell defect in aplastic anaemia. In:  Schrezenmeier H,  Bacigalupo A editor. Aplastic Anaemia. Cambridge, UK: Cambridge University Press; 1999;p. 2–20
  48. Martin SJ, Green DR. Apoptosis and cancer: The failure of controls on cell death and cell survival. Crit Opin Hematol. 1995;18:137–153
  49. Nakao S, Matsushima K, Young N. Deficient interleukin-1 production by aplastic anaemia monocytes. Br J Haematol. 1989;71:431–433
  50. Nash RA, Burstein SA, Storb R, et al.  Thrombocytopenia in dogs induced by granulocyte-macrophage colony stimulating factor: Increased destruction of circulating platelets. Blood. 1995;86:1765–1775
  51. Nimer SD, Leung DHY, Wolin MJ, et al.  Serum stem cell factor levels in patients with aplastic anemia. Int J Hematol. 1994;60:185–189
  52. Nimer SD, Paquette RL, Ireland P, et al.  A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia. Exp Hematol. 1994;22:875–880
  53. Nissen C, Tichelli A, Gratwohl A, et al.  Failure of rhGM-CSF therapy in aplastic anemia patients with very severe neutropenia. Blood. 1988;72:2045–2046
  54. Nissen C, Wodnar-Filipowicz A, Slanicka Krieger M, et al.  Persistent growth impairment of bone marrow stroma after antilymphocyte globulin treatment for severe aplastic anaemia and its association with relapse. Eur J Haematol. 1995;55:255–261
  55. Notaro R, Cimmino A, Tabanni D, et al.  In vivo telomere dynamics of human hemopoietic stem cells. In: Proc Natl Acad Sci USA. 94:1997;p. 13782–13785
  56. Novitsky N, Jacobs P. Immunosuppressive therapy in bone marrow aplasia: The stroma functions normally to support hemopoiesis. Exp Hematol. 1995;23:1472–1477
  57. Ohara A, Kojima S, Hamajima N, et al.  Myelodysplasia and acute myeloid leukemia as a late clonal complication in children with acquired aplastic anemia. Blood. 1997;90:1009–1013
  58. Philpott NJ, Scopes J, Marsh JCW, et al.  Increased apoptosis in aplastic anemia bone marrow progenitor cells: Possible pathophysiological significance. Exp Haematol. 1995;23:1642–1648
  59. Podesta M, Paggio G, Frassoni F, et al.  Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:1011–1017
  60. Raghavachar A, Ganser A, Freund M, et al.  Long term interleukin-3 and intensive immunosuppression in the treatment of aplastic anemia. Cytokines Mol Ther. 1996;2:215–223
  61. Rosenfeld S, Kinball J, Vining D, et al.  Superior result of combination immunosuppressive therapy with antithymocyte globulin and cyclosporine A in severe aplastic anemia. Blood. 1995;85:3058–3064
  62. Schrezenmeier H, Jenal M, Hermann F, et al.  Quantitative analysis of cobblestone area forming cells in bone marrow of patients with aplastic anemia by limiting dilution assay. Blood. 1996;88:4474–4480
  63. Schrezenmeier H, Marsh JCW, Stromeyer P, et al.  A phase I/II trial of recombinant human interleukin-6 in patients with aplastic anaemia. Br J Haematol. 1995;90:283–292
  64. Schrezenmeier H, Noe G, Raghavachar A, et al.  Serum erythropoietin and serum transferin receptor levels in aplastic anaemia. Br J Haematol. 1994;88:286–294
  65. Schrezenmeier H, Raghavachar A, Heimpel . Granulocyte-macrophage colony stimulating factor in the serum of patients with aplastic anemia. Clin Invest. 1993;71:102–108
  66. Scopes J, Bagnara M, Gordon-Smith EC, et al.  Haemopoietic progenitor cells are reduced in aplastic anaemia. Br J Haematol. 1994;81:427–430
  67. Scopes J, Daly S, Atkinson R, et al.  Aplastic anemia: Evidence for dysfunctional bone marrow progenitor cells and the corrective effect of granulocyte colony stimulating factor in vitro. Blood. 1996;87:3179–3185
  68. Slanicka-Krieger M, Nissen C, et al.  Stem cell factor in aplastic anaemia: In vitro expression in bone marrow stroma and fibroblast cultures. Eur J Haematol. 1995;54:262–269
  69. Socie G, Henry AM, Bacigalupo A, et al.  Malignant tumours occurring after treatment of aplastic anemia. European Bone Marrow Transplant Severe Aplastic Anemia Working Party. N Engl J Med. 1993;329:1152–1157
  70. Sonoda Y, Ohno Y, Fujii H, et al.  Multilineage response in aplastic anemia patients following long-term administration of filgrastim (recombinant human granulocyte colony stimulating factor). Stem Cells. 1993;11:543–554
  71. Sonoda Y, Yashige H, Fujii H, et al.  Bilineage response in refractory aplastic anemia patients following long term administration of recombinant human granulocyte-macrophage colony stimulating factor. Eur J Haematol. 1992;48:41–44
  72. Stark R, Andre C, Thierry D, et al.  The expression of cytokine and cytokine receptor genes in long term bone marrow culture in congenital and acquired marrow hypoplasias. Br J Haematol. 1993;83:560–566
  73. Takahashi M, Yoshida Y, Kaku K, et al.  Phase II study of recombinant human granulocyte colony stimulating factor in myelodysplastic syndrome and aplastic anemia. Acta Haematol. 1993;89:189–194
  74. Testa NG, de Wynter EA, Weaver A. The study of hemopoietic stem cells in patients: Concepts, approaches and cautionary tales. Ann Oncol. 1996;7(suppl 2):5–8 abstr
  75. Tichelli A, Gratwohl A, Wursch A, et al.  Late haematological complications in severe aplastic anaemia. Br J Haematol. 1988;69:413–418
  76. Vadhan-Raj S, Buerscher S, Broxmeyer HE, et al.  Stimulation of myelopoiesis in patients with aplastic anemia by recombinant human granulocyte-macrophage stimulating factor. N Engl J Med. 1988;319:1628–1634
  77. Vaziri H, Dragowska W, Allsopp RC, et al.  Evidence for a mitotic clock in human hemopoietic stem cells: Loss of telomere DNA with age. In: Proc Natl Acad Sci USA. 91:1994;p. 9857–9860
  78. Walsh CE, Liu JM, Anderson SM, et al.  A trial of recombinant human interleukin-1 in patients with severe refractory aplastic anaemia. Br J Haematol. 1992;80:106–110
  79. Weite K, Gabrilove J, Bronchud MH, et al.  Filgrastim (r-metHuG-CSF): The first 10 years. Blood. 1996;88:1907–1929
  80. Wodmar-Filipowicz A, Chlouskaia E, Manz CY, et al.  Effect of flt3 ligand on in vitro growdi and expansion of colony forming bone marrow cells from patients with aplastic anemia. Exp Hematol. 1997;25:573–581
  81. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, et al.  Flt-3 ligand level reflects hemopoietic progenitor cell function in aplastic anemia and chemotherapy induced bone marrow aplasia. Blood. 1996;88:4493–4499
  82. Wodnar-Filipowicz A, Yancik S, Moser Y, et al.  Levels of soluble stem cell factor in serum of patients with aplastic anemia. Blood. 1993;81:3259–3264
  83. Wynn RF, Cross MA, Hatton C, et al.  Accelerated telomere shortening in young recipients of allogeneic bone marrow transplants. Lancet. 1998;351:178–181
  84. Wynn RF, Cross MA, Testa NG. Telomeres and haemopoiesis. Br J Haematol. 1998;103:591–593
  85. Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995;85:3367–3377
  86. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365–1372

PII: S0037-1963(00)90032-5

Seminars in Hematology
Volume 37, Issue 1 , Pages 81-90 , January 2000

Article Tools